# Nebulised BromAc in Healthy Volunteers

> **NCT05220605** · PHASE1 · COMPLETED · sponsor: **Mucpharm Pty Ltd** · enrollment: 12 (actual)

## Conditions studied

- COVID-19 Pneumonia
- Bromelains Adverse Reaction
- Acetylcysteine Adverse Reaction
- Mucus; Plug
- COVID-19 Acute Respiratory Distress Syndrome

## Interventions

- **DRUG:** BromAc

## Key facts

- **NCT ID:** NCT05220605
- **Lead sponsor:** Mucpharm Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-27
- **Primary completion:** 2022-08-14
- **Final completion:** 2022-08-25
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2022-09-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05220605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05220605, "Nebulised BromAc in Healthy Volunteers". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05220605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*